2019 Fiscal Year ResultsBy alcyon|2020-01-16T17:37:06+01:00March 11th, 2020|Financial calendar|0 Comments Read More
Biomed Event: January 28, 2020 – Paris, FranceBy alcyon|2019-12-12T16:53:05+01:00January 28th, 2020|Investor Event|0 Comments Read More
J.P. Morgan Healthcare Conference: January 13 to 16, 2020 – San Francisco, USABy alcyon|2019-12-12T16:57:58+01:00January 13th, 2020|Investor Event|0 Comments Read More
Oddo Forum: January 9 & 10, 2020 – Lyon, FranceBy alcyon|2019-12-12T16:51:14+01:00January 9th, 2020|Investor Event|0 Comments Read More
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)20190527-PR-Last-patient-TG4010-1L-ENBy alcyon|2019-06-05T12:11:55+02:00May 27th, 2019|Press release, TG4010|0 Comments Read More
Combined General Meeting of May 22, 201920190522-TG-AGM-2019-ENBy alcyon|2019-06-03T19:38:01+02:00May 22nd, 2019|Press release|0 Comments Read More
Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 201920190513-Resultats-Q1-2019-EN-By alcyon|2019-06-03T22:36:47+02:00May 13th, 2019|Press release|0 Comments Read More
Transgene receives FDA IND Clearance for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer20190513 PR IND TG4050 ENBy alcyon|2019-06-17T14:22:03+02:00May 13th, 2019|Myvac, Press release, TG4050|0 Comments Read More
Availability of Preparatory Documents for the Combined General Meeting of May 22, 201920190509MISE A DISPO AG - USBy alcyon|2019-06-03T19:37:09+02:00May 9th, 2019|Press release|0 Comments Read More
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies20190502 - TG-AZ agreement - ENGBy alcyon|2019-06-03T19:41:55+02:00May 2nd, 2019|Invir.IO, Press release|0 Comments Read More
